1. Home
  2. GNPX vs MGRX Comparison

GNPX vs MGRX Comparison

Compare GNPX & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.55

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

N/A

Current Price

$0.37

Market Cap

7.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
MGRX
Founded
2009
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
7.1M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
GNPX
MGRX
Price
$0.55
$0.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
365.0K
622.7K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.17
EPS
N/A
N/A
Revenue
N/A
$456,021.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.26
52 Week High
$12.97
$2.75

Technical Indicators

Market Signals
Indicator
GNPX
MGRX
Relative Strength Index (RSI) 42.11 47.11
Support Level $0.42 $0.34
Resistance Level $2.12 $0.48
Average True Range (ATR) 0.05 0.05
MACD 0.02 0.00
Stochastic Oscillator 33.74 49.35

Price Performance

Historical Comparison
GNPX
MGRX

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Share on Social Networks: